• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Estimated Effectiveness of Prior SARS-CoV-2 BA.1 or BA.2 Infection and Booster Vaccination Against Omicron BA.5 Subvariant Infection.

作者信息

Jang Eun Jung, Choe Young June, Kim Ryu Kyung, Lee Sangwon, Park Seon Kyeong, Park Young-Joon

机构信息

Korea Disease Control and Prevention Agency, Cheongju, South Korea.

Korea University Anam Hospital, Seoul, South Korea.

出版信息

JAMA Netw Open. 2023 Mar 1;6(3):e232578. doi: 10.1001/jamanetworkopen.2023.2578.

DOI:10.1001/jamanetworkopen.2023.2578
PMID:36897593
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12068789/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d15b/12068789/fcc367ba7755/jamanetwopen-e232578-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d15b/12068789/fcc367ba7755/jamanetwopen-e232578-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d15b/12068789/fcc367ba7755/jamanetwopen-e232578-g001.jpg

相似文献

1
Estimated Effectiveness of Prior SARS-CoV-2 BA.1 or BA.2 Infection and Booster Vaccination Against Omicron BA.5 Subvariant Infection.既往感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）BA.1或BA.2毒株及接种加强针疫苗对奥密克戎BA.5亚变体感染的估计有效性
JAMA Netw Open. 2023 Mar 1;6(3):e232578. doi: 10.1001/jamanetworkopen.2023.2578.
2
Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged ≥60 years: Estimates over calendar time and by time since administration during prevalent circulation of different Omicron subvariants, Italy, 2022-2023.对≥60 岁人群接种二价（原始/Omicron BA.4-5）mRNA 疫苗加强针对严重 COVID-19 的有效性：意大利，2022-2023 年，根据不同 Omicron 亚变体流行期间的日历时间和接种后时间估算
Vaccine. 2024 Oct 3;42(23):126026. doi: 10.1016/j.vaccine.2024.05.074. Epub 2024 Jun 3.
3
Transmission characteristics and inactivated vaccine effectiveness against transmission of the SARS-CoV-2 Omicron BA.2 variant in Shenzhen, China.中国深圳 SARS-CoV-2 奥密克戎 BA.2 变异株传播特性和灭活疫苗对传播的有效性。
Front Immunol. 2024 Jan 8;14:1290279. doi: 10.3389/fimmu.2023.1290279. eCollection 2023.
4
Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case-control analysis.既往感染人群中，与 COVID-19 mRNA 疫苗（基础免疫或加强针）接种和奥密克戎变异株 BA.1 刺突蛋白 SARS-CoV-2 感染的相关性：一项病例对照研究。
PLoS Med. 2022 Dec 1;19(12):e1004136. doi: 10.1371/journal.pmed.1004136. eCollection 2022 Dec.
5
Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.BNT162b2 和 CoronaVac 新冠疫苗对奥密克戎 BA.2 亚谱系引起的 SARS-CoV-2 无症状和有症状感染的有效性：一项前瞻性队列研究。
Lancet Infect Dis. 2023 Apr;23(4):421-434. doi: 10.1016/S1473-3099(22)00732-0. Epub 2022 Dec 12.
6
Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.丹麦全国性观察研究：与 SARS-CoV-2 奥密克戎亚变体 BA.2.86 和后代 JN.1 相关的相对疫苗保护、疾病严重程度和症状。
Lancet Infect Dis. 2024 Sep;24(9):964-973. doi: 10.1016/S1473-3099(24)00220-2. Epub 2024 May 15.
7
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.美国儿童中含 COVID-19 奥密克戎 BA.1 变异株的疫苗的临时安全性和免疫原性：一项开放标签、非随机化 3 期临床试验。
Lancet Infect Dis. 2024 Jul;24(7):687-697. doi: 10.1016/S1473-3099(24)00101-4. Epub 2024 Mar 19.
8
Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.估计 BNT162b2 疫苗对美国 5 至 11 岁儿童感染德尔塔和奥密克戎变异株的有效性。
JAMA Netw Open. 2022 Dec 1;5(12):e2246915. doi: 10.1001/jamanetworkopen.2022.46915.
9
Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.中国广东奥密克戎 BA.2 感染突破性感染用灭活 COVID-19 疫苗加强接种的效果：一项队列研究。
Front Immunol. 2023 Oct 17;14:1257360. doi: 10.3389/fimmu.2023.1257360. eCollection 2023.
10
Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.2021 年 8 月至 2022 年 3 月，英国青少年在先前感染和接种疫苗后对 delta（B.1.617.2）和 omicron（B.1.1.529）BA.1 和 BA.2 SARS-CoV-2 变异株的症状性感染的保护作用：一项全国性、观察性、基于检测的病例对照研究。
Lancet Infect Dis. 2023 Apr;23(4):435-444. doi: 10.1016/S1473-3099(22)00729-0. Epub 2022 Nov 24.

引用本文的文献

1
SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals.二价 BA.4/5 新冠病毒疫苗接种后，既往感染和未感染个体的针对 SARS-CoV-2 的细胞和体液免疫。
Nat Commun. 2024 Apr 9;15(1):3077. doi: 10.1038/s41467-024-47429-8.
2
Effectiveness of BNT162b2 BA.4/5 Bivalent mRNA Vaccine Against Symptomatic COVID-19 Among Immunocompetent Individuals Testing at a Large US Retail Pharmacy.辉瑞-BioNTech 二价疫苗对美国大型零售连锁药店免疫功能正常人群中 COVID-19 有症状感染者的有效性
J Infect Dis. 2024 Mar 14;229(3):648-659. doi: 10.1093/infdis/jiad474.

本文引用的文献

1
Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants.既往感染严重急性呼吸综合征冠状病毒2对奥密克戎BA.4和BA.5亚变体的保护作用。
N Engl J Med. 2022 Oct 27;387(17):1620-1622. doi: 10.1056/NEJMc2209306. Epub 2022 Oct 5.
2
Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes.基础疫苗和加强疫苗接种以及先前感染与 SARS-CoV-2 感染和严重 COVID-19 结局的关联。
JAMA. 2022 Oct 11;328(14):1415-1426. doi: 10.1001/jama.2022.17876.
3
Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review.
加强针对 SARS-CoV-2 奥密克戎变异株的 COVID-19 疫苗接种：系统评价。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2062983. doi: 10.1080/21645515.2022.2062983. Epub 2022 May 2.
4
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.新冠病毒疫苗接种和既往感染后对 SARS-CoV-2 的保护作用。
N Engl J Med. 2022 Mar 31;386(13):1207-1220. doi: 10.1056/NEJMoa2118691. Epub 2022 Feb 16.
5
Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants.接种疫苗无论是在感染 SARS-CoV-2 之前还是之后，都会引发强烈的体液免疫反应和能够有效中和变异株的抗体。
Sci Immunol. 2022 Feb 18;7(68):eabn8014. doi: 10.1126/sciimmunol.abn8014.
6
mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021.mRNA 疫苗对老年人因 COVID-19 住院和死亡的有效性：基于葡萄牙国家健康登记数据链接的队列研究，2021 年 2 月至 8 月。
Euro Surveill. 2021 Sep;26(38). doi: 10.2807/1560-7917.ES.2021.26.38.2100833.